Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Trovagene Investor Presentation - May 2019

Corporate Presentation

Please select from the documents below
............................................................................................................................ 

Trovagene Oncology Investor Presentation - May 1, 2019